Including what it doesn’t say, and what “FDA-cleared” actually means
If you have peripheral neuropathy and you have searched for help, you have seen the ads. Light therapy. Cold laser. Infrared. Photobiomodulation. Usually accompanied by the phrase “FDA-cleared,” often beside a percentage.
The research on light therapy for nerve pain is real, and some of it is encouraging. It is also narrower than the marketing suggests, and the phrase “FDA-cleared” does not mean what most of those pages imply. Both things are worth knowing before you spend money.
What the research actually shows
The most current synthesis is a 2025 review in Lasers in Medical Science, which examined 23 studies published between 2015 and 2025. Its conclusion: photobiomodulation is “a promising, safe and effective adjunctive therapy for diabetic neuropathy.”
Note the word adjunctive. It means alongside other care, not instead of it.
A 2023 systematic review in Current Diabetes Reviews pooled eight studies and reported improvements in neuropathic pain and nerve conduction velocity, along with reduced plantar pressure distribution — which matters because elevated plantar pressure is a risk factor for foot ulceration.
So: multiple independent research groups, looking at overlapping evidence, arriving at cautiously positive conclusions. That is a genuine signal, and anyone telling you light therapy is pure quackery is overstating in the other direction.
The two things those summaries leave out
First, the doses are not standardized. The 2025 review is direct about this. Its stated limitation is that “the absence of standardized dosimetry among the studies remains a major challenge,” and it closes by saying “further research is needed to define optimized and reproducible therapeutic protocols.”
The review does identify where effects clustered — wavelengths around 630–670 nm or 808–904 nm, energy densities of 3–10 J/cm², power output of 45–100 mW, and a minimum of roughly twelve sessions. But a range that wide across 23 studies is not a protocol. It means the field has not yet agreed on what dose to give, for how long, to whom.
The practical translation: two clinics can both truthfully say they offer “light therapy backed by research” while delivering completely different treatments, and the research cannot tell you which one is closer to the studies that worked.
Second — and this is the part almost nobody mentions — nearly all of this research is in diabetic peripheral neuropathy.
Both reviews above studied people with type 2 diabetes. That is not an accident of sampling; it is where the funding and the trials have gone.
If your neuropathy is diabetic, this evidence is about you. If you have been told your neuropathy is idiopathic, or you have small fiber neuropathy, or your symptoms began after chemotherapy, or after a viral illness — the evidence base is substantially thinner, and results in diabetic neuropathy do not automatically transfer. The underlying nerve injury is not the same, so there is no strong reason to assume the response would be.
This is the single most common gap between what the studies examined and what patients are told they apply to.
What “FDA-cleared” actually means here
This is where the marketing does the most work.
Most therapeutic light devices in this category are cleared under 21 CFR 890.5500, the FDA’s classification for an infrared lamp. The regulation defines it as “a device intended for medical purposes that emits energy at infrared frequencies (approximately 700 nanometers to 50,000 nanometers) to provide topical heating.”
That is the cleared indication. Topical heating.
These devices go through the 510(k) pathway, which establishes that a device is substantially equivalent to one already on the market. It is not a finding that the device treats any particular disease. The FDA has not evaluated and cleared these devices as treatments for peripheral neuropathy, and no clearance in this category says they repair nerves.
So when a clinic page says “FDA-cleared” next to a claim about reversing neuropathy, both halves may be sourced from different places, and the sentence as a whole implies something no regulator has said. “FDA-cleared infrared heating device” is accurate. “FDA-cleared to treat neuropathy” is not a thing that exists.
Ask any clinic offering this to tell you the device’s 510(k) number and what indication it was cleared for. The information is public. A practice that knows its own equipment will have the answer.
What to do with this
If you are considering light therapy for nerve pain, the honest position is:
- The evidence is real, cautiously positive, and describes it as an adjunct, not a cure
- The strongest evidence is in diabetic neuropathy specifically
- Dosing is not standardized, so “we offer light therapy” tells you very little about what you will actually receive
- “FDA-cleared” refers to topical heating, not to treating neuropathy
- Nobody can honestly quote you a success rate for reversing neuropathy, because that research does not exist
None of that means don’t consider it. It means ask better questions, and be cautious with anyone who answers them with a percentage.
The more important question usually comes earlier anyway: has anyone established why your nerves are affected? A large share of people carrying an “idiopathic” label have never had a full workup for metabolic, nutritional, autoimmune, vascular, or toxic contributors. Treating a cause you have identified is a different proposition from treating a symptom you have not explained.
If you are in the Oklahoma City area and want to talk through what has and has not been ruled out in your case, you can start with a free phone consultation.
Reviewed by Alvin Philipose, DC, ICCP · 23 August 2026
This article is provided for general educational purposes only. It is not medical advice, it is not a diagnosis, and it is not an offer of treatment or a description of services. It has not been evaluated by the Food and Drug Administration. Individual results vary and no outcome is guaranteed. Discuss any treatment decision with a qualified healthcare provider who knows your history. If you are experiencing sudden weakness, difficulty breathing or swallowing, new bowel or bladder changes, or a wound or infection on your foot, seek emergency care.
Sources
- Dosimetric parameters and clinical outcomes of photobiomodulation in diabetic neuropathy: a concise review. Lasers in Medical Science, 2025. DOI: 10.1007/s10103-025-04701-7
- Korada HY, Arora E, Maiya GA, et al. Effectiveness of Photobiomodulation Therapy on Neuropathic Pain, Nerve Conduction and Plantar Pressure Distribution in Diabetic Peripheral Neuropathy — A Systematic Review. Current Diabetes Reviews, 2023. PMID: 37622461
- 21 CFR 890.5500 — Infrared lamp, U.S. Code of Federal Regulations
